Thermo Fisher Scientific Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$388.00 | Lkpk | Wwqdhkvjw |
Thermo Fisher's Core Business Strengths Offset Decline in COVID-19 Testing
Business Strategy and Outlook
Thermo Fisher didn’t just come out of the toughest two years for the global economy unscathed, the company managed to deliver its best year ever despite challenges around the economy and spending budgets. Being the premier life science supplier and having an unmatched portfolio of products, resources, and manufacturing capabilities have allowed the firm to be among the first to market with a reliable coronavirus test and at capacity needed to meet massive demand. The coronavirus pandemic reaffirmed the company's entrenched and dominant positioning with the supply chain.